Breadcrumb

[A17-06] Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2017-02-10 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 409 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A18-67] Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-46] Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-28] Pembrolizumab (non-small cell lung cancer) - Addendum to Commission A17-06
Status: Commission completed

[A17-23] Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A16-55] Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A15-33] Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2017-05-15 Extract of dossier assessment 409 kBPDFdownload file
2017-05-15 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V [PDF, 409 kB]

Federal Joint Committee (G-BA)

2017-08-03 A G-BA decision was published.

G-BA documents on this decision

Federal Joint Committee (G-BA)

2017-08-03 A G-BA decision was published.

G-BA documents on this decision

Press releases

2017-05-15 Pembrolizumab in non-small cell lung cancer: hint of considerable added benefit



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close